Distribution of total net revenues

SEK million

2019

Jan-Mar

2018

Jan-Mar

2018

Jan-Dec

12 mth

Apr 2018-Mar 2019

12 mth

Apr 2017-Mar 2018

Zubsolv® US

161.7

131.1

621.5

652.1

502.8

Zubsolv - ex US

-

-

36.2

36.2

5.6

Zubsolv – total

161.7

131.1

657.7

688.3

508.4

Abstral® royalties

10.9

5.8

118.8

123.9

110.3

Edluar® royalties

1.7

2.8

6.6

5.5

15.5

OX-CLI

-

-

-

-

21.8

Total

174.3

139.7

783.1

817.7

656.0

 

Key figures

SEK m, unless otherwise stated

2019

Jan-Mar

2018

Jan-Mar

2018

Jan-Dec

12 mth

Apr 2018-Mar 2019

12 mth

Apr 2017-Mar 2018

Net revenues

174.3

139.7

783.1

817.7

656.0

whereof Zubsolv® US net revenue

161.7

131.1

621.5

652.1

502.8

Cost of goods sold

-25.3

-48.4

-171.8

-148.7

-166.6

Operating expenses

-147.9

-113.1

-515.6

-550.4

-430.6

EBIT

1.1

-21.8

95.8

118.7

58.8

EBIT margin, %

0.6

-15.6

12.2

14.5

9.0

US EBIT

71.9

25.3

198.3

244.8

98.6

US EBIT margin, %

44.5

19.3

31.9

37.5

19.6

EBITDA

12.0

-16.6

116.6

145.2

79.7

Earnings per share, before dilution, SEK

0.41

-0.75

3.99

5.15

0.92

Earnings per share, after dilution, SEK

0.40

-0.75

3.93

5.05

0.92

Cash flow from operating activities

50.9

106.3

242.0

186.9

224.4

Cash and cash equivalents

647.4

437.5

589.8

647.4

437.5

Cash flow

SEK million

2019 Jan-Mar

2018 Jan-Mar

2018 Jan-Dec

Depreciation/amortization and impairment

10.9

5.2

20.8

Change in provisions

12.4

57.1

45.6

Share based payments

3.1

1.0

2.1

Exchange rate income and expenses

-3.5

-2.6

-6.5

Total

22.9

60.7

61.9